Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #69259 on Biotech Values
DewDiligence
12/04/08 7:15 AM
#69450 RE: DewDiligence #69259
Filng iHub Company Date Reference AGIX 10/08 #msg-31947587 ARTE 12/08 #msg-33895436 INGN 12/08 #msg-33947783 GTOP 9/08 #msg-32249160 MIIS 11/08 #msg-33720220 REX 11/08 #msg-32189097 TPPH 2/08 #msg-26765260 VRA 10/07 #msg-18053275
12/27/08 7:39 PM
#70709 RE: DewDiligence #69259
Acquired Premium Deal iHub Company Buyer to Market Value Date Reference GNLB GSK 465% $57M 10/08 #msg-33209281 MEMY Roche 319% $50M 11/08 #msg-33787598 KOSN BMY 233% $190M 5/08 #msg-29647147 COLY PFE 167% $165M 11/07 #msg-24600805 IOMI Intercell 147% $190M 5/08 #msg-29232165 BTRX Stiefel 136% $150M 6/08 #msg-30201906 SGXP LLY 119% $64M 7/08 #msg-30547648 ENCY PFE 118% $350M 2/08 #msg-26978155 TRCA Ipsen 104% $660M 6/08 #msg-29795183 CRY.to MDT 97% $380M 9/08 #msg-32421462 Speedel NVS 94% $880M 7/08 #msg-30588524 MNT JNJ 92% $1.1B 11/08 #msg-33879830 SIRT GSK 85% $620M 4/08 #msg-28705020 Ventana Roche 72% $3.4B 1/08 #msg-30912677 Jerini Shire *71% $520M 7/08 #msg-30452872 Acambis SNY 64% $550M 7/08 #msg-30990498 SCRX Shionogi 61% $1.4B 9/08 #msg-31859174 ALO KG ‡†54% $1.6B 11/08 #msg-33763449 MEDI AZN ‡‡53% $15.2B 4/07 #msg-19020387 MLNM Takeda 53% $8.8B 4/08 #msg-28365383 PCOP LGND ***52% $75M 9/08 #msg-32404474 OMRI JNJ ‡*51% $465M 11/08 #msg-33762745 IMCL LLY †††51% $6.5B 10/08 #msg-32662830 LEVP VPHM ††49% $440M 7/08 #msg-30704409 PHRM CELG 46% $2.9B 11/07 #msg-24645394 BRL TEVA **42% $9.0B 7/08 #msg-30792830 MOGN Eisai 39% $3.9B 12/07 #msg-25163775 CGPI Galderma 30% $420M 2/08 #msg-28286522 APPX Fresenius †29% $940M 7/08 #msg-30498388 Zentiva SNY ‡‡26% $2.6B 9/08 #msg-32327005 ARI.to Roche ‡15% $190M 7/08 #msg-30904056 PGLA Avexa ® ® 12/08 #msg-34341452 NTMD Archemix ® ® 11/08 #msg-33656969 NUVO ARCA ® ® 9/08 #msg-32420015 ®Reverse merger with private or non-US company. ‡†Based on closing price 8/21/08, the day before KG announced initial buyout offer. ‡*Based on 11/20/08 close. *199% premium to volume-weighted price during preceding 3 months. **Premium based on 7/16/08 close; $9B price includes assumption of debt. ***Premium excludes 0.50/sh contingency. †Premium reaches 63% if earn-out met. ††Premium reaches 103% if earn-out met; base price subject to collar. †††Premium relative to 7/30/08 close, the day before BMY announced first buyout offer. ‡Number is misleading inasmuch as Arius announced in May 2008 that it was pursued by an unnamed suitor. ‡‡Premium relative to commencement of bidding.